Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394416 · ClinicalTrials.gov registry record · Phase 3
Trial of Imatinib for Hospitalized Adults With COVID-19
A Phase 3 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT04394416: Clinical Trial Phase 3 study, sponsored by University of Maryland, Baltimore.
NCT04394416 is a Phase 3 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 21 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04394416, a Phase 3 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Primary Outcome
The primary endpoint is all-cause mortality at Day 28 after the start of imatinib/placebo.
Interventions
- DRUG Placebo oral tablet
- DRUG Imatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2025-07-17 |
| Phase | Phase 3 |
Why NCT04394416 stopped before completion
NCT04394416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04394416 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04394416 about?
NCT04394416 is a clinical study titled "Trial of Imatinib for Hospitalized Adults With COVID-19". This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
What is the current status of trial NCT04394416?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2020-06-02. Estimated completion is 2025-07-17.
What interventions are being tested in trial NCT04394416?
The interventions under investigation include: Placebo oral tablet (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT04394416?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04394416's enrollment target sits among peer trials
21 1953rd of 2000 higher than 45 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI